KDNY
NASDAQChinook Therapeutics Inc.
Latest news
25 items- 13D/GSEC Form SC 13D/A filed by Chinook Therapeutics Inc. (Amendment)SC 13D/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
- SECSEC Form 15-12G filed by Chinook Therapeutics Inc.15-12G - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form EFFECT filed by Chinook Therapeutics Inc.EFFECT - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- 13D/GSEC Form SC 13D filed by Chinook Therapeutics Inc.SC 13D - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form S-8 POS filed by Chinook Therapeutics Inc.S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form POSASR filed by Chinook Therapeutics Inc.POSASR - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECSEC Form POS AM filed by Chinook Therapeutics Inc.POS AM - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- SECChinook Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
- INSIDERSEC Form 4: Thomas Dolca returned 13,300 shares to the company, closing all direct ownership in the company4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
- INSIDERSEC Form 4 filed by Oxtoby Andrew4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
- INSIDERSEC Form 4: Krishnan Mahesh returned 1,275 shares to the company, closing all direct ownership in the company4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
- INSIDERSEC Form 4: King Andrew James returned 19,157 shares to the company, closing all direct ownership in the company4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
- INSIDERSEC Form 4: Griffin Michelle Renee returned 3,300 shares to the company, closing all direct ownership in the company4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
- INSIDERSEC Form 4: Greenman William Mariner returned 23,643 shares to the company, closing all direct ownership in the company4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
- INSIDERSEC Form 4: Frohlich Tom returned 150,777 shares to the company, closing all direct ownership in the company4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
KDNY FAQ
7 questionsWhat does Chinook Therapeutics Inc. do?
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research...Where does KDNY stock trade?
Chinook Therapeutics Inc. (KDNY) is listed on NASDAQ.What sector and industry is KDNY in?
Chinook Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Chinook Therapeutics Inc. go public?
Chinook Therapeutics Inc. (KDNY) completed its IPO in 2015.What are analysts saying about KDNY?
Chinook Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Wedbush: Neutral with a $4200.00 price target on 2023-08-08. Recent price targets range from $3000.00 to $4300.00.What companies are similar to KDNY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KDNY side-by-side with any of them on Quantisnow.How can I track KDNY on Quantisnow?
Quantisnow aggregates Chinook Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KDNY to receive live email and push alerts on every new disclosure.